A VALIDATED PREDICTION MODEL AND NOMOGRAM FOR RISK OF RECURRENCE IN EARLY BREAST CANCER PATIENTS
Author(s)
Witteveen A1, Vliegen IM2, Siesling S3, IJzerman MJ4
1University of Twente, MIRA Institute for Biomedical Technology & Technical Medicine, Enschede, The Netherlands, 2University of Twente, Centre for Healthcare Operations Improvement and Research (CHOIR), Enschede, The Netherlands, 3Comprehensive Cancer Centre the Netherlands (IKNL), Utrecht, The Netherlands, 4MIRA Institute for Biomedical Technology & Technical Medicine and University of Twente, Enschede, The Netherlands
OBJECTIVES The objective of this study is to develop and validate a conditional logistic regression model for the prediction of locoregional recurrence (LRR) of breast cancer. To make a translation to clinical practice a web based nomogram was made. METHODS Women first diagnosed with early breast cancer (without distant metastasis or ingrowth in the chest wall or skin) between 2003-2006 were selected from the Netherlands Cancer Registry (n=39,929). Risk factors for LRRs within five year of the primary treatment were determined using logistic regression. Risks were determined per year, conditional on not being diagnosed with recurrence in the previous year. The presence of interaction and collinearity in the nomogram was assessed, as well as the discrimination by means of the area under the ROC curve and calibration by the Hosmer-Lemeshow goodness-of-fit test in deciles. Data on primary tumours diagnosed between 2007-2008 from a selection of Dutch hospitals was used for external validation of the performance of the nomogram (n=13,792). RESULTS The final model included the variables grade, size, multifocality, and nodal involvement of the primary tumour, type of surgery, and whether patients were treated with radio-, chemo- or hormone therapy. The modelling group showed an area under the ROC curve of 0.82, 0.74, 0.67, 0.70 and 0.60 respectively per subsequent year after primary treatment. The calibration was sufficient. All effects in the validation group were in the same direction, and the estimates in the validation group did not differ significantly from the modelling group. CONCLUSIONS This validated nomogram can be used as an instrument to aid clinical decision-making and to identify patients with a high risk of breast cancer recurrence who might benefit from a more intensive follow-up after breast cancer.
Conference/Value in Health Info
2014-11, ISPOR Europe 2014, Amsterdam, The Netherlands
Value in Health, Vol. 17, No. 7 (November 2014)
Code
PCN34
Topic
Epidemiology & Public Health
Disease
Oncology